PHARMAC seeking views on new breast cancer medicine


15 January 2020 - PHARMAC has reached a provisional agreement with medicine supplier Pfizer to fund palbociclib (marketed as Ibrance) for first-line and second-line treatment of certain types of breast cancer.

Consultation has gone out today to health professionals and is available on our website for anyone wanting to have their say about the proposal to fund Ibrance.

Read PHARMAC Consultation

Michael Wonder

Posted by:

Michael Wonder